Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2010, Article ID 852028, 6 pages
http://dx.doi.org/10.1155/2010/852028
Review Article

When Should Surgical Cytoreduction in Advanced Ovarian Cancer Take Place?

Oxford Gynaecological Cancer Centre Surgery and Diagnostics, Level 0, Churchill Hospital, Oxford OX3 7JL, UK

Received 29 April 2009; Accepted 13 September 2009

Academic Editor: Dennis S. Chi

Copyright © 2010 Igor E. Martinek and Sean Kehoe. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Permuth-Wey and T. A. Sellers, “Epidemiology of ovarian cancer,” Methods in Molecular Biology, vol. 472, pp. 413–437, 2009. View at Publisher · View at Google Scholar
  2. R. W. Hunter, N. D. E. Alexander, and W. P. Soutter, “Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis?” American Journal of Obstetrics and Gynecology, vol. 166, no. 2, pp. 504–511, 1992. View at Google Scholar
  3. D. G. Allen, A. P. M. Heintz, and F. W. M. M. Touw, “A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary,” European Journal of Gynaecological Oncology, vol. 16, no. 5, pp. 349–356, 1995. View at Google Scholar
  4. R. E. Bristow, R. S. Tomacruz, D. K. Armstrong, E. L. Trimble, and F. J. Montz, “Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis,” Journal of Clinical Oncology, vol. 20, no. 5, pp. 1248–1259, 2002. View at Publisher · View at Google Scholar
  5. M. E. L. van der Burg, M. van Lent, M. Buyse et al., “The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer,” The New England Journal of Medicine, vol. 332, no. 10, pp. 629–634, 1995. View at Publisher · View at Google Scholar
  6. P. G. Rose, S. Nerenstone, M. F. Brady et al., “Secondary surgical cytoreduction for advanced ovarian carcinoma,” The New England Journal of Medicine, vol. 351, no. 24, pp. 2489–2497+2567, 2004. View at Publisher · View at Google Scholar · View at PubMed
  7. C. W. E. Redman, J. Warwick, D. M. Luesley, R. Varma, F. G. Lawton, and G. R. P. Blackledge, “Intervention debulking surgery in advanced epithelial ovarian cancer,” British Journal of Obstetrics and Gynaecology, vol. 101, no. 2, pp. 142–146, 1994. View at Google Scholar
  8. S. Tangjitgamol, S. Manusirivithaya, M. Laopaiboon, and P. Lumbiganon, “Interval debulking surgery for advanced epithelial ovarian cancer,” Cochrane Database of Systematic Reviews, no. 2, Article ID CD006014, 2009. View at Publisher · View at Google Scholar · View at PubMed
  9. J. Morrison, A. Swanton, S. Collins, and S. Kehoe, “Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer,” Cochrane Database of Systematic Reviews, no. 4, Article ID CD005343, 2007. View at Publisher · View at Google Scholar · View at PubMed
  10. P.-E. Colombo, A. Mourregot, M. Fabbro et al., “Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients,” European Journal of Surgical Oncology, vol. 35, no. 2, pp. 135–143, 2009. View at Publisher · View at Google Scholar · View at PubMed
  11. H. Oksefjell, B. Sandstad, and C. Tropé, “The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer,” Annals of Oncology, vol. 20, no. 2, pp. 286–293, 2009. View at Publisher · View at Google Scholar · View at PubMed
  12. M. A. F. Hegazy, R. A. F. Hegazi, M. A. Elshafei et al., “Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma,” World Journal of Surgical Oncology, vol. 3, article 57, 2005. View at Publisher · View at Google Scholar · View at PubMed
  13. T. Le, W. Faught, L. Hopkins, and M. Fung-Kee-Fung, “Can surgical debulking reverse platinum resistance in patients with metastatic epithelial ovarian cancer?” Journal of Obstetrics and Gynaecology Canada, vol. 31, no. 1, pp. 42–47, 2009. View at Google Scholar
  14. A. Rafii, B. Deval, J.-F. Geay et al., “Treatment of FIGO stage IV ovarian carcinoma: results of primary surgery or interval surgery after neoadjuvant chemotherapy: a retrospective study,” International Journal of Gynecological Cancer, vol. 17, no. 4, pp. 777–783, 2007. View at Publisher · View at Google Scholar · View at PubMed
  15. I. Vergote, I. De Wever, W. Tjalma, M. Van Gramberen, J. Decloedt, and P. van Dam, “Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients,” Gynecologic Oncology, vol. 71, no. 3, pp. 431–436, 1998. View at Publisher · View at Google Scholar · View at PubMed
  16. C. T. Griffiths, “Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma,” National Cancer Institute Monograph, vol. 42, pp. 101–104, 1975. View at Google Scholar
  17. I. T. Magrath, S. Lwanga, W. Carswell, and N. Harrison, “Surgical reduction of tumour bulk in management of abdominal Burkitt's lymphoma,” British Medical Journal, vol. 2, no. 914, pp. 308–312, 1974. View at Google Scholar
  18. C. T. Griffiths and A. F. Fuller, “Intensive surgical and chemotherapeutic management of advanced ovarian cancer,” Surgical Clinics of North America, vol. 58, no. 1, pp. 131–142, 1978. View at Google Scholar
  19. A. L. Covens, “A critique of surgical cytoreduction in advanced ovarian cancer,” Gynecologic Oncology, vol. 78, no. 3, pp. 269–274, 2000. View at Publisher · View at Google Scholar · View at PubMed
  20. W. J. Hoskins, B. N. Bundy, J. T. Thigpen, and G. A. Omura, “The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study,” Gynecologic Oncology, vol. 47, no. 2, pp. 159–166, 1992. View at Publisher · View at Google Scholar
  21. S. M. Eisenkop and N. M. Spirtos, “Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with “biological aggressiveness” and survival?” Gynecologic Oncology, vol. 82, no. 3, pp. 435–441, 2001. View at Publisher · View at Google Scholar · View at PubMed
  22. D. S. Chi, E. L. Eisenhauer, J. Lang et al., “What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?” Gynecologic Oncology, vol. 103, no. 2, pp. 559–564, 2006. View at Publisher · View at Google Scholar · View at PubMed
  23. W. J. Hoskins, “Epithelial ovarian carcinoma: principles of primary surgery,” Gynecologic Oncology, vol. 55, no. 3, pp. S91–S96, 1994. View at Publisher · View at Google Scholar · View at PubMed
  24. S. M. Eisenkop, N. M. Spirtos, and W.-C. M. Lin, ““Optimal” cytoreduction for advanced epithelial ovarian cancer: a commentary,” Gynecologic Oncology, vol. 103, no. 1, pp. 329–335, 2006. View at Publisher · View at Google Scholar · View at PubMed
  25. J. S. Berek, N. F. Hacker, L. D. Lagasse, R. K. Nieberg, and R. M. Elashoff, “Survival of patients following secondary cytoreductive surgery in ovarian cancer,” Obstetrics and Gynecology, vol. 61, no. 2, pp. 189–193, 1983. View at Google Scholar
  26. S. Kehoe, J. Powell, S. Wilson, and C. Woodman, “The influence of the operating surgeon's specialisation on patient survival in ovarian carcinoma,” British Journal of Cancer, vol. 70, no. 5, pp. 1014–1017, 1994. View at Google Scholar
  27. M. Morris, D. M. Gershenson, and J. T. Wharton, “Secondary cytoreductive surgery in epithelial ovarian cancer: nonresponders to first-line therapy,” Gynecologic Oncology, vol. 33, no. 1, pp. 1–5, 1989. View at Google Scholar
  28. D. S. Chi, E. S. Venkatraman, V. Masson, and W. J. Hoskins, “The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma,” Gynecologic Oncology, vol. 77, no. 2, pp. 227–231, 2000. View at Publisher · View at Google Scholar · View at PubMed
  29. S. Memarzadeh, S. B. Lee, J. S. Berek, and R. P. Farias-Eisner, “CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer,” International Journal of Gynecological Cancer, vol. 13, no. 2, pp. 120–124, 2003. View at Publisher · View at Google Scholar
  30. R. E. Bristow, L. R. Duska, N. C. Lambrou et al., “A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography,” Cancer, vol. 89, no. 7, pp. 1532–1540, 2000. View at Publisher · View at Google Scholar
  31. I. Vergote, T. van Gorp, F. Amant, K. Leunen, P. Neven, and P. Berteloot, “Timing of debulking surgery in advanced ovarian cancer,” International Journal of Gynecological Cancer, vol. 18, supplement 1, pp. 11–19, 2008. View at Publisher · View at Google Scholar · View at PubMed
  32. S. Kehoe, “Maximal cytoreductive surgery in advanced ovarian cancer,” Reviews in Gynaecological Practice, vol. 5, no. 4, pp. 207–211, 2005. View at Publisher · View at Google Scholar
  33. G. H. Eltabbakh, S. L. Mount, B. Beatty, L. Simmons-Arnold, K. Cooper, and A. Morgan, “Factors associated with cytoreducibility among women with ovarian carcinoma,” Gynecologic Oncology, vol. 95, no. 2, pp. 377–383, 2004. View at Publisher · View at Google Scholar · View at PubMed
  34. P. Boudou-Rouquette, P. Pautier, P. Morice, and C. Lhommé, “Prognostic and predictive factors in epithelial ovarian cancer,” Bulletin du Cancer, vol. 96, no. 4, pp. 425–437, 2009. View at Publisher · View at Google Scholar · View at PubMed